We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02674607
Recruitment Status : Completed
First Posted : February 4, 2016
Last Update Posted : October 25, 2017
Information provided by (Responsible Party):
Professor Mohamed Elshanshory, Tanta University

Brief Summary:
The aim of this study is to evaluate the possible immunologic effects of spirulina in children with beta thalassemia.

Condition or disease Intervention/treatment Phase
Beta Thalassemia Major Dietary Supplement: Spirulina Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children
Study Start Date : October 2015
Actual Primary Completion Date : October 2017
Actual Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia

Arm Intervention/treatment
Experimental: patients
thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
Dietary Supplement: Spirulina
No Intervention: controls
thirty healthy children of matched age and sex

Primary Outcome Measures :
  1. cluster of differentiation (CD4/CD25) ratio [ Time Frame: 3 months ]
  2. cluster of differentiation (CD33/CD11b/Lin) ratio [ Time Frame: 3 months ]
  3. serum immunoglobulins levels [ Time Frame: 3 months ]
  4. serum levels of interferon gamma [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • children with thalassemia major

Exclusion Criteria:

  • children with other chronic hemolytic anemias

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02674607

Layout table for location information
Faculty of Medicine- Tanta University
Tanta, Gharbia, Egypt, 0000
Sponsors and Collaborators
Tanta University
Layout table for investigator information
Principal Investigator: Mohamed R El-Shanshory, MD professor of pediatrics- head of hematooncology unit of pediatric department- Tanta University
Layout table for additonal information
Responsible Party: Professor Mohamed Elshanshory, head of pediatric hematology and oncology unit, Tanta University
ClinicalTrials.gov Identifier: NCT02674607    
Other Study ID Numbers: 2132/10/13
First Posted: February 4, 2016    Key Record Dates
Last Update Posted: October 25, 2017
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn